In 1995, changes in our hospital formulary were made to limit an outbreak of vancomycinresistant enterococci and resulted in decreased usage of cephalosporins, imipenem, clindamycin, and vancomycin and increased usage of b-lactam/b-lactamase-inhibitor antibiotics. In this report, the effect of this formulary change on other resistant pathogens is described. Following the formulary change, there was a reduction in the monthly number (mean { SD) of patients with methicillinresistant Staphylococcus aureus (from 21.9 { 8.1 to 17.2 { 7.2 patients/1,000 discharges; P Å .03) and ceftazidime-resistant Klebsiella pneumoniae (from 8.6 { 4.3 to 5.7 { 4.0 patients/1,000 discharges; P Å .02). However, there was an increase in the number of patients with cultures positive for cefotaxime-resistant Acinetobacter species (from 2.4 { 2.2 to 5.4 { 4.0 patients/1,000 discharges; P Å .02). Altering an antibiotic formulary may be a possible mechanism to contain the spread of selected resistant pathogens. However, close surveillance is needed to detect the emergence of other resistant pathogens.
In the past decade, outbreaks of emerging resistant pathogens stricted. The success of this intervention to limit the spread of vancomycin-resistant enterococci and Clostridium difficile has (e.g., vancomycin-resistant enterococci and Enterobacteriaceae having extended-spectrum b-lactamases) have been described been previously reported [15] . In this study, we examined the effect of this intervention on other nosocomial pathogens. [1 -7] , and established pathogens (e.g., methicillinresistant Staphylococcus aureus) have persisted [8 -10] and infiltrated the community [9, 10] . Guidelines have emphasized aggressive infection-control measures to limit the spread of Methods resistant bacteria within hospitals [11, 12] . However, it is troubThe Department of Veterans Affairs Medical Center at ling that many of these outbreaks have occurred in the era of Brooklyn is a university-affiliated tertiary care facility. Microbiuniversal precautions, and investigations describing the failure ology records from 1 January 1993 through 30 April 1997 were of a variety of infection-control measures have been reported reviewed to identify all patients whose cultures yielded the [1 -3, 8, 9, 13, 14] . Clearly, new approaches are needed to following bacteria: methicillin-resistant S. aureus, ceftazidimelimit the nosocomial spread of resistant bacteria.
resistant Klebsiella pneumoniae, ceftazidime-resistant Enterobacter species, ceftazidime-resistant Pseudomonas aeruginosa, See editorial response by Rice on pages 1067 -70.
ticarcillin-resistant P. aeruginosa, and cefotaxime-resistant Acinetobacter species. These organisms were selected to assess the In 1993, infection-control measures were instituted at our impact of formulary changes on the major nosocomial pathohospital to limit the spread of vancomycin-resistant enterogens at our institution. Only patients whose cultures of blood cocci. When the failure of these measures was realized [2] , we or other sterile body fluids or of wound, respiratory tract, or attempted to control the outbreak by changing the hospital urinary tract specimens yielding the targeted pathogens were formulary. In May 1995, the use of b-lactam/b-lactamaseincluded. The number of new patients each month who had a inhibitor antibiotics was emphasized and the use of third-generpositive culture was recorded. For each pathogen, patients were ation cephalosporins, vancomycin, and clindamycin was reincluded only once. All isolates were identified with standard microbiological methods, and susceptibility testing was performed according to the guidelines of the National Committee 3] ). lary, and their use was suggested in place of the cephalosporins. In addition, pharmacy records from 1 January 1993 through For the 29 months before the intervention, the monthly incidence of new patients with cultures positive for methicillin-31 December 1996 were reviewed to determine the overall antibiotic usage per month. The usage and expenditures for resistant S. aureus was 21.9 { 8.1 per 1,000 discharges ( figure  1 ). For the 23 months following the intervention, this decreased the following antibiotics were reviewed: ampicillin, penicillin, piperacillin, nafcillin, ampicillin/sulbactam, piperacillin/tazoto 17.2 { 7.2 patients per 1,000 discharges (P Å .03). The incidence of new patients with ceftazidime-resistant K. pneubactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, imipenem, ciprofloxacin, vancomycin, clindamycin, metronidamoniae also decreased, from 8.6 { 4.3 to 5.7 { 4.0 per 1,000 discharges (P Å .02; figure 1 ). Susceptibility testing of the zole, amikacin, and gentamicin. To adjust for fluctuating prices, antibiotic costs were calculated with use of 1996 prices.
isolates from the 50 patients identified just prior to the intervention in May 1995 revealed that only 6% were resistant to Infection-control measures directed against vancomycinresistant enterococci were initiated in April 1993, as previously cefotaxime and cefoxitin, suggesting the presence in most isolates of a b-lactamase that could be inhibited by sulbactam, described [2] . In May 1995, in addition to the changes in the hospital antibiotic formulary, contact precautions were extazobactam, and clavulanate. Of the isolates from the 50 patients identified immediately following the intervention, 10% panded to also include patients with C. difficile colitis and diarrhea of unknown etiology [15] . No specific precautions were resistant to cefotaxime and cefoxitin (P Å .07).
Compared with that in the baseline period, there was no were undertaken for patients whose cultures yielded any of the bacteria studied in this investigation.
change in the incidence of new patients with ceftazidime-resistant Enterobacter species (5.3 { 3.2 vs. 4.1 { 2.0 per 1,000 Statistical analysis. The incidence of each nosocomial pathogen is reported as the number of new patients with a posidischarges [P Å .10]) or ceftazidime-resistant P. aeruginosa (3.8 { 2.9 vs. 3.3 { 2.8 per 1,000 discharges [P Å .5]). tive culture per 1,000 discharges per month from the medical and surgical services. The usage of antibiotics is reported as Similarly, there was no difference in the incidence of new patients with ticarcillin-resistant P. aeruginosa before and after grams utilized per month. Results are expressed as mean { SD. Student's t test and x 2 analysis were used to compare preinterthe intervention (11.4 { 4.7 vs. 12.2 { 4.2 [P Å .5]). However, the incidence of new patients with cultures positive for cefotaxvention and postintervention data. Stepwise multiple linear regression analysis was performed to determine any correlation ime-resistant Acinetobacter species rose significantly (figure 1), from 2.4 { 2.2 to 5.4 { 4.0 per 1,000 discharges before between the number of patients with cultures yielding methicillin-resistant S. aureus or ceftazidime-resistant K. pneumoniae and after the intervention, respectively (P Å .02). Of 25 isolates collected in 1997, all but one were resistant to piperacillin/ and the following variables: number of discharges, average length of stay, and the usage of vancomycin, clindamycin, and tazobactam. The number of hospital discharges from the medical and third-generation cephalosporins. All data were analyzed with use of TRUE EPISTAT software (Epistat Services, Houston). A surgical services averaged 569 { 50 per month before the intervention. Following the intervention, this decreased to 513 two-tailed P value of £.05 was considered significant.
{ 50 per month (P õ .001). In addition, the average length of stay on the acute care services also decreased, from 15.0 { 1.5 to 13.2 { 1.8 days (P õ .001). Multiple regression analysis Results revealed that only usage of third-generation cephalosporins was significantly correlated with the number of patients with methiUsage of the three targeted antibiotics (cefotaxime, clindamycin, and vancomycin) significantly decreased following the cillin-resistant S. aureus (P Å .003) and ceftazidime-resistant K. pneumoniae (P õ .001). The number of new patients requirintervention in May 1995. Monthly usage of cefotaxime fell from 1,432 { 283 to 164 { 78 g/mo (P õ .001), that of ing contact isolation (those with C. difficile or vancomycinresistant enterococci) also decreased following the intervention, clindamycin from 594 { 167 to 108 { 62 g/mo (P õ .001), and that of vancomycin from 588 { 136 to 313 { 98 g/mo from 10.7 { 4.7 patients per month to 6.2 { 4.5 patients per month (P Å .002). (P õ .001). In addition, significant reductions in the use of four antibiotics not targeted by the intervention were observed:
Review of microbiological records revealed that 61% of 2,447 S. aureus isolates collected from 1993 through 1995 cefazolin (from 724 { 187 to 531 { 209 g/mo [P Å .002]), ceftazidime (from 677 { 197 to 229 { 117 g/mo [P õ .001]), were susceptible to methicillin; in 1996, 65% of 678 isolates were susceptible (P Å .04). For K. pneumoniae, 66% of 1,374 imipenem (from 136 { 57 to 89 { 47 g/mo [P Å .004]), and gentamicin (from 43.8 { 14.1 to 30.6 { 6.9 g/mo [P õ .001]).
isolates received by the microbiology laboratory from 1993 through 1995 were susceptible to ceftazidime, compared with Administration of the two b-lactamase-inhibitor combination antibiotics dramatically increased: that of ampicillin/sulbactam 88% of 336 isolates collected in 1996 (P õ .001). The percentage of isolates of P. aeruginosa susceptible to ceftazidime also to 3,326 { 853 g/mo and that of piperacillin/tazobactam to 1,898 { 761 g/mo. Total antibiotic costs before and after the increased, from 92% of 1,560 isolates collected from 1993 / 9c65$$my14 04-06-99 08:04:27 cida UC: CID through 1995 to 96% of 438 isolates collected in 1996 Methicillin-resistant S. aureus is a frequent nosocomial pathogen [19] . We noted a significant decline in the incidence of (P Å .003). There was no change in the percentage of Enterobacter species isolates susceptible to ceftazidime or in the perpatients with cultures positive for methicillin-resistant S. aureus following a reduction in vancomycin, clindamycin, and cephalocentage of P. aeruginosa isolates susceptible to ticarcillin. There was a significant decrease in the percentage of Acinetosporin usage and an increase in ampicillin/sulbactam and piperacillin-tazobactam usage. Although most methicillin-resistant S. bacter species isolates susceptible to cefotaxime, from 51% of 392 isolates collected from 1993 through 1995 to 37% of 155 aureus isolates are resistant to b-lactamase-inhibitor combination antibiotics, negating the effect of penicillinase restores much isolates collected in 1996 (P Å .005).
of the activity of ampicillin [20] [21] [22] . b-Lactam/b-lactamaseinhibitor antibiotics have shown activity in the treatment of experDiscussion imental endocarditis due to methicillin-resistant S. aureus [20] [21] [22] , although high levels may be required [22, 23] . Therefore, There is an increasing trend for nosocomial infections to be colonization with methicillin-resistant S. aureus may be less caused by more-resistant pathogens [17] , and as new antimicrobial likely to occur in a patient receiving a b-lactam/b-lactamaseagents have been developed, bacteria have acquired new mechainhibitor antibiotic (than in one receiving a cephalosporin). Emnisms of resistance [18] . Although infection-control protocols may phasizing this class of antibiotics may reduce the incidence of help limit the spread of nosocomial pathogens, once introduced infection with this pathogen. into the hospital, pathogens are often difficult to eradicate [1-3, K. pneumoniae strains having extended-spectrum b-lacta- 8-10, 13, 14] . The emergence of a particular pathogen may be mases have been isolated with increasing frequency [4] , and enhanced by the selective pressures exerted by the antibiotics used hospital outbreaks have been described [5 -7] . Some of these at a hospital. Changing the antibiotic usage may be an effective method for limiting the spread of resistant pathogens.
outbreaks have involved strains with b-lactamases inhibited / 9c65$$my14 04-06-99 08:04:27 cida UC: CID
